Note 14 - Segments (Tables)

3 Months Ended

Mar. 31, 2022

Three Months Ended March 31, 2022	Diagnostics			Therapeutics			Corporate			Total
Research and development expenses	$	989,887		$	179,367		$	—		$	1,169,254
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾		—			—			1,787,152			1,787,152
Depreciation and amortization ⁽²⁾		6,040			—			16,838			22,878
Loss from operations ⁽³⁾		(995,927	)		(179,367	)		(1,803,990	)		(2,979,284	)
Other expense ⁽⁴⁾		—			—			(7,961	)		(7,961	)
Net loss		(995,927	)		(179,367	)		(1,811,951	)		(2,987,245	)
Total assets, net of depreciation and amortization:
United States	$	150,920		$	—		$	3,034,316		$	3,185,236
International		393,753			—			23,136			416,889
Capital expenditures		40,221			—			1,796			42,017

Three Months Ended March 31, 2021	Diagnostics			Therapeutics			Corporate			Total
License revenue	$	22,486		$	—		$	—		$	22,486
Grant and other revenue		101,251			—			—			101,251
Total revenue		123,737			—			—			123,737
Research and development expenses		1,094,390			128,364			—			1,222,754
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾		—			2,006			2,210,991			2,212,997
Depreciation and amortization ⁽²⁾		6,040			—			11,708			17,748
Loss from operations ⁽³⁾		(976,693	)		(130,370	)		(2,222,699	)		(3,329,762	)
Other income ⁽⁴⁾		—			—			362,870			362,870
Net loss		(976,693	)		(130,370	)		(1,859,829	)		(2,966,892	)
Total assets, net of depreciation and amortization:
United States	$	160,669		$	—		$	9,723,212		$	9,883,881
International		193,194			—			—			193,194
Capital expenditures		—			—			—			—